Deciphera Pharmaceuticals Inc. raised nearly an additional $60 million as underwriters from the recent public offering fully exercised their overallotment option.
Underwriters purchased an additional 1,621,621 common shares of the Waltham, Mass.-based biopharmaceutical company at $37 apiece, increasing gross proceeds from the offering to $460 million. When the offering closed on Aug. 19, Deciphera had sold 10,810,810 common shares at the same price.
The company plans to use net proceeds to fund clinical trials of its cancer drugs as well as for working capital purposes among others.
J.P. Morgan, Piper Jaffray and Jefferies were the joint book-running managers for the offering. Guggenheim Securities was the lead manager for the offering, while SunTrust Robinson Humphrey was co-manager for the offering.
